Anteris Technologies Global Corp.
Close on Oct 19, 2026
- Market cap
- $601.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 27, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | – | – |
Press releases
Announcements Anteris Technologies Global filed with the SEC
Anteris Technologies Announces Results for the Second Quarter of 2026
Results of operations · EX-99.1 to Form 8-K
Results for announcement to the market
Results of operations · EX-99.2 to Form 8-K
lodgement of a cleansing notice under the Corporations Act 2001 (Cth) was heard earlier today and the Court has granted the relief sought.
Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Technologies Global Corp. (ASX:AVR) – request for trading halt under ASX Listing Rule 17.1
Regulation FD disclosure · EX-99.1 to Form 8-K
2001 (Cth) ( Corporations Act ) was not lodged within the prescribed 5 business day period. Anteris intends to lodge a cleansing notice today in relation to the issue of the
Regulation FD disclosure · EX-99.2 to Form 8-K
Anteris Announces Results for the First Quarter of 2026
Results of operations · EX-99.1 to Form 8-K
Results for announcement to the market
Results of operations · EX-99.2 to Form 8-K
Results for announcement to the market
Results of operations · EX-99.1 to Form 8-K
Anteris Reports 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.2 to Form 8-K
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Technologies Presents Data from 100 DurAVR ® THV Patients at PCR London Valves
Regulation FD disclosure · EX-99.1 to Form 8-K
Results for announcement to the market
Results of operations · EX-99.1 to Form 8-K
Anteris Announces Results for the Third Quarter of 2025
Results of operations · EX-99.2 to Form 8-K
FDA Approves Anteris’s DurAVR ® THV Global Pivotal Trial (the “PARADIGM Trial”)
Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Technologies Announces First Patients Treated in DurAVR ® THV Global Pivotal Trial (the “PARADIGM Trial”)
Regulation FD disclosure · EX-99.1 to Form 8-K
October 2025 NASDAQ: AVR | ASX: AVR
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Receives First European Regulatory Clearance to Commence DurAVR ® THV Global Pivotal Trial (the “PARADIGM Trial”)
Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
NOTICE OF ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS
Other events · EX-99.2 to Form 8-K
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Results for announcement to the market
Results of operations · EX-99.1 to Form 8-K
Anteris Announces Results for the Second Quarter of 2025
Results of operations · EX-99.2 to Form 8-K
Waiver from ASX Listing Rule 7.1
Other events · EX-99.1 to Form 8-K
Anteris Technologies Global Corp. (“ATGC”)
Results of operations · EX-99.1 to Form 8-K
Anteris Announces Results for the First Quarter of 2025
Results of operations · EX-99.2 to Form 8-K
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR ® THV
Regulation FD disclosure · EX-99.1 to Form 8-K
Anteris Reports One-Year Patient Outcomes for DurAVR ® THV
Regulation FD disclosure · EX-99.1 to Form 8-K
For the year ended December 31, 2024
Results of operations · EX-99.1 to Form 8-K
Anteris Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.2 to Form 8-K
of Over-Allotment Option and End of Stabilisation Period
Regulation FD disclosure · EX-99.1 to Form 8-K